{
  "nctrialId": "HC-1643",
  "title": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of IBS-225 (serotonin modulator) in Patients With Multiple Sclerosis",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of IBS-225 (serotonin modulator) in Patients With Multiple Sclerosis",
  "sponsor": "Princess Margaret Cancer Centre",
  "indication": "Multiple Sclerosis",
  "phase": "Phase 2/Phase 3",
  "fileName": "HC-1643.json",
  "fileSize": 287100,
  "date": "2024-04-26",
  "completionDate": "2027-11-08",
  "drugName": "IBS-225 (serotonin modulator)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Not yet recruiting",
  "description": "This is a randomized double-blind, placebo-controlled multi-center study designed to evaluate the efficacy and safety of IBS-225 (serotonin modulator) in patients with Multiple Sclerosis. The study will enroll approximately 238 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 19-61 years\n- Confirmed diagnosis of Multiple Sclerosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}